Article Details
Retrieved on: 2022-09-11 08:24:43
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “These updated POSEIDON results at nearly four years of follow-up show ...
Article found on: www.miragenews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here